Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT-2 Inhibitors for Albuminuria in LN and AAV
NCT07035834Phase 4Not yet recruiting
- Sponsor
- University of Naples Federico II
- Start
- Sep 2025
- Primary completion
- Sep 2026
01
Overview
Phase 4, open-label, single-arm trial in chronic kidney disease (CKD), sponsored by University of Naples Federico II. Primary endpoint: Variation of albuminuria at 6 months. Planned start Sep 2025; status: not yet recruiting.
02
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07035834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035834.